Key result
NT-proBNP combined with LVEF demonstrated high predictive value for anthracycline-induced cardiotoxicity in breast cancer patients, yielding an AUC of 0.898.
Why the study?
To determine the predictive value of NT-proBNP combined with echocardiography in diagnosing anthracyclines-induced chronic cardiotoxicity.
Does combining NT-proBNP with echocardiography improve the early prediction of anthracycline-induced cardiotoxicity in female breast cancer patients?
Observational (n=80)
No
Does combining NT-proBNP with echocardiography improve the early prediction of anthracycline-induced cardiotoxicity in female breast cancer patients?
Effect estimate: AUC 0.898 (95% CI 0.829-0.966)
Combining NT-proBNP with echocardiography provides a highly accurate early predictive value for anthracycline-induced cardiotoxicity in breast cancer patients.
May inform cardiotoxicity surveillance in breast cancer; hypothesis-generating and requires prospective validation.
Objective Determine the predictive value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) combined with echocardiography in the diagnosis of anthracyclines-induced chronic cardiotoxicity. Methods A total of 80 female breast cancer patients from January 2019 to October 2021 were included in our hospital. Twenty-six patients with cardiotoxicity were divided into the cardiac impairment group, and the 54 patients without cardiotoxicity were classified into the normal control group. NT-proBNP levels and cardiac echocardiography were measured before the start of the chemotherapy cycle, in cycle 3 of the chemotherapy, and after the chemotherapy cycle in all patients. Results After three cycles of chemotherapy and chemotherapy, the levels of NT-proBNP in patients of the two groups were significantly higher than those before chemotherapy ( P < 0.05). The levels of NT-proBNP in the cardiac injury group after three cycles of chemotherapy and chemotherapy were higher than those in the normal control group at the same time point ( P < 0.05). The LVEF of patients in the cardiac impairment group after chemotherapy was lower than that before chemotherapy, and the LVEF after chemotherapy was lower than that in the normal control group ( P < 0.05). NT-proBNP had a negative correlation with LVEF ( r = −0.549, P < 0.001). The AUC of NT-proBNP in combination with LVEF for predicting cardiotoxicity in our patient was 0.898(95%CI:0.829–0.966). Conclusion NT-proBNP combined with echocardiography has clinical significance in the detection of anthracyclines-induced cardiotoxicity, and it can detect early myocardial injury induced by anthracyclines, with early prediction value. It is important to protect heart function and judge prognosis.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2022) conducted an observational in Breast cancer (anthracycline-induced cardiotoxicity) (n=80). NT-proBNP combined with LVEF vs. NT-proBNP alone or LVEF alone was evaluated on Prediction of anthracycline-induced cardiotoxicity (AUC 0.898, 95% CI 0.829-0.966). NT-proBNP combined with LVEF demonstrated high predictive value for anthracycline-induced cardiotoxicity in breast cancer patients, yielding an AUC of 0.898.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: